Last Updated: August 20, 6:15pm IGN AdnKronos
Stefano Portolano, CEO of the American pharmaceutical group Celgene in Italy, is convinced of this, speaking at the Rimini Meeting at the round table 'Strategies for biomedical research'
Milan, 20 Aug. (Adnkronos Salute) – "A great deal has been done in Italy to encourage biomedical research". Especially in a moment of crisis like this, "the most important thing is to invest in innovation" and in this sense "the spending review gave a very positive message: innovative drugs and orphan drugs "for the treatment of rare diseases" were excluded from some of the cutting measures contained in the decree. This is the right path, we must continue to follow it". He is convinced of this Stefano Portolano, CEO of the American pharmaceutical group Celgene in Italy, who spoke at the Rimini Meeting at the round table 'Strategies for biomedical research'.
To concretely support those who work in this sector in our country, explains the CEO, "it is necessary to make people understand what true innovation is and to encourage it. We need to be able to distinguish and not lump everything together. Only in this way will industries be stimulated to produce real innovation, rather than drugs or technologies more or less similar to what already exists just to conquer a slice of the market". Support for true innovation, explains Portolano, translates into "new treatments for the sick and a cascade of development and jobs".
"Celgene has invested and is investing a lot in Italy", continues the CEO. "In clinical trials we are often the first country for the number of patients recruited, and the fact that the spending review has rewarded orphan drugs and innovative drugs will allow us to continue to believe in Italy". A square on which it is worth focusing, Portolano is keen to highlight, also for "the great excellence of doctors and operators in particular in the hematological sector in which we operate".
"obj
